These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 1847845

  • 41. [Development of carboplatin].
    Tsukagoshi S.
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
    [Abstract] [Full Text] [Related]

  • 42. Reversal of cisplatin resistance by the 1,4-benzothiazepine derivative, JTV-519.
    Nakamura T, Koizumi F, Kaneko N, Tamura T, Chiwaki F, Koh Y, Akutagawa S, Saijo N, Nishio K.
    Jpn J Cancer Res; 2001 Jun; 92(6):597-602. PubMed ID: 11429046
    [Abstract] [Full Text] [Related]

  • 43. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M, Abe Y, Fujimori S, Hamamoto A, Inoue Y, Miyazaki N, Oida Y, Ikoma N, Ohnishi Y, Yamazaki H, Ueyama Y, Nakamura M.
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
    Chen YM, Liu JM, Wu MF, Wu HW, Lin WC, Tsai CM, Perng RP, Whang-Peng J.
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
    [Abstract] [Full Text] [Related]

  • 47. A Phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly.
    Chen YM, Perng RP, Tsai CM, Whang-Peng J.
    J Thorac Oncol; 2006 Feb; 1(2):141-5. PubMed ID: 17409843
    [Abstract] [Full Text] [Related]

  • 48. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
    Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.
    Cancer Res; 1993 Jun 01; 53(11):2581-6. PubMed ID: 8388318
    [Abstract] [Full Text] [Related]

  • 49. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
    Theile D, Kos M.
    Toxicol Lett; 2016 Feb 03; 242():47-52. PubMed ID: 26656794
    [Abstract] [Full Text] [Related]

  • 50. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
    Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT.
    Mol Cancer Ther; 2004 Dec 03; 3(12):1543-9. PubMed ID: 15634647
    [Abstract] [Full Text] [Related]

  • 51. In vitro antitumor activity of a new platinum complex, cis-malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum (II) (SKI 2053R), against human lung and stomach cancer cell lines.
    Hong WS, Kim HT, Kim KH, Kim DK.
    Anticancer Res; 1995 Dec 03; 15(1):51-4. PubMed ID: 7733640
    [Abstract] [Full Text] [Related]

  • 52. In vitro antitumor activity of mitomycin C derivative (RM-49) and new anticancer antibiotics (FK973) against lung cancer cell lines determined by tetrazolium dye (MTT) assay.
    Horiuchi N, Nakagawa K, Sasaki Y, Minato K, Fujiwara Y, Nezu K, Ohe Y, Saijo N.
    Cancer Chemother Pharmacol; 1988 Dec 03; 22(3):246-50. PubMed ID: 2842080
    [Abstract] [Full Text] [Related]

  • 53. Current standards of care in small-cell and non-small-cell lung cancer.
    Schiller JH.
    Oncology; 2001 Dec 03; 61 Suppl 1():3-13. PubMed ID: 11598409
    [Abstract] [Full Text] [Related]

  • 54. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J, Meng Q, Zhao Y, Chen X, Cai L.
    BMC Cancer; 2016 Jul 13; 16():470. PubMed ID: 27411790
    [Abstract] [Full Text] [Related]

  • 55. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
    Wouters BG, Wang LH, Brown JM.
    Ann Oncol; 1999 Jul 13; 10 Suppl 5():S29-33. PubMed ID: 10582136
    [Abstract] [Full Text] [Related]

  • 56. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, Prager D, Monberg MJ, Ye Z, Obasaju CK.
    J Clin Oncol; 2006 Oct 20; 24(30):4840-7. PubMed ID: 17050869
    [Abstract] [Full Text] [Related]

  • 57. The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay.
    Roed H, Vindeløv LL, Christensen IJ, Spang-Thomsen M, Hansen HH.
    Eur J Cancer Clin Oncol; 1988 Feb 20; 24(2):247-53. PubMed ID: 2833402
    [Abstract] [Full Text] [Related]

  • 58. [Evidence based chemotherapy for lung cancer].
    Watanabe H, Saijo N.
    Gan To Kagaku Ryoho; 2000 Jan 20; 27(1):30-43. PubMed ID: 10660731
    [Abstract] [Full Text] [Related]

  • 59. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N, Lam YM, Pym J, Campling BG.
    Cancer; 1996 May 01; 77(9):1797-808. PubMed ID: 8646677
    [Abstract] [Full Text] [Related]

  • 60. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A, Trojan A, Burnand B, Giannelli M.
    Lung Cancer; 2008 Jan 01; 59(1):1-11. PubMed ID: 17720276
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.